Department of Gastrointestinal Surgery, Subei People's Hospital of Jiangsu Province (Clinical Medical College of Yangzhou University), Yangzhou, People's Republic of China.
Int J Cancer. 2013 Mar 1;132(5):993-1003. doi: 10.1002/ijc.27715. Epub 2012 Oct 5.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most common malignant tumors with poor prognosis due to extremely high malignancy, low rate of eligibility for surgical resection and chemoradiation resistance. Increasing evidence indicate that the interaction between activated pancreatic stellate cells (PSCs) and PDAC cells plays an important role in the development of PDAC. By producing high levels of cytokines, chemotactic factors, growth factors and excessive extracellular matrix (ECM), PSCs create desmoplasia and a hypoxic microenvironment that promote the initiation, development, evasion of immune surveillance, invasion, metastasis and resistance to chemoradiation of PDAC. Therefore, targeting the interaction between PSCs and PDAC cells may represent a novel therapeutic approach to advanced PDAC, especially therapies that target PSCs of the pancreatic tumor microenvironment.
胰腺导管腺癌（PDAC）是最常见的恶性肿瘤之一，由于其极高的恶性程度、手术切除和放化疗的低适应证率，预后较差。越来越多的证据表明，激活的胰腺星状细胞（PSCs）与 PDAC 细胞之间的相互作用在 PDAC 的发展中起着重要作用。PSCs 通过产生高水平的细胞因子、趋化因子、生长因子和细胞外基质（ECM），导致形成纤维组织增生和缺氧的微环境，从而促进 PDAC 的起始、发展、免疫逃避、侵袭、转移和对放化疗的耐药性。因此，靶向 PSCs 与 PDAC 细胞之间的相互作用可能代表一种治疗晚期 PDAC 的新方法，特别是针对胰腺肿瘤微环境中的 PSCs 的治疗方法。
